

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CREB binding protein (CREBBP; CBP); E1A binding protein p300 (EP300; p300); hypoxia-inducible factor 1 α (HIF1A; HIF1 α)	<i>In vitro</i> and mouse studies suggest peptide inhibitors of HIF1A could help treat cancer. In human breast cancer cells, two stabilized peptide helix mimetics that block the interaction between HIF1A and its coactivators CBP or p300 decreased hypoxia-inducible transcription of target genes including <i>VEGF-A</i> compared with vehicle. In mouse xenograft models of human renal cell carcinoma, one of the mimetics decreased tumor volume compared with no treatment. Next steps could include testing the peptide mimetic in additional animal models. At least seven companies have HIF1A inhibitors in Phase II or earlier testing to treat various cancers.	Patent and licensing status unavailable	Kushal, S. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Sept. 9, 2013; doi:10.1073/pnas.1312473110 Contact: Paramjit S. Arora, New York University, New York, N.Y. e-mail: arora@nyu.edu Contact: Bogdan Z. Olenyuk, University of Southern California, Los Angeles, Calif. e-mail: bogdan@usc.edu
		SciBX 6(39); doi:10.1038/scibx.2013.1088 Published online Oct. 10, 2013		